A*STAR Scientists Identify Potential Drug Target for Inflammatory Diseases Including Cancers
News Nov 22, 2012
A*STAR scientists have identified the enzyme, telomerase, as a cause of chronic inflammation in human cancers.
Chronic inflammation is now recognized as a key underlying cause for the development of many human cancers, autoimmune disorders, neurodegenerative diseases, and metabolic diseases such as diabetes.
This enzyme, which is known to be responsible for providing cancer cells the endless ability to divide, is now found to also jumpstart and maintain chronic inflammation in cancers.
In identifying this enzyme, inflammation can be prevented or reduced, and the common ailments can be alleviated. This discovery has considerable impact on healthcare because developing drugs to target telomerase can greatly reduce healthcare costs.
Currently, the annual costs and expenses associated with cancer and metabolic diseases such as diabetes amount to about $132 billion in the US alone.
Although many safe and effective anti-inflammatory drugs such as aspirin are currently available on the market, these drugs sometimes have side effects because blocking inflammation is typically detrimental to normal physiology.
Hence there exists a need for the development of cost-effective drugs that are targeted, so as to minimize side effects.
This collaborative research was conducted by scientists at A*STAR's Institute of Molecular and Cell Biology (IMCB) led by Assoc Prof Vinay Tergaonkar, A*STAR's Genome Institute of Singapore (GIS) and National University of Singapore.
Other clinical collaborators include Cancer Science Institute of Singapore and Duke-NUS Graduate Medical School.
The research findings were published on Nov. 18, 2012, in the prestigious scientific journal, Nature Cell Biology.
The team identified that telomerase directly regulates the production of inflammatory molecules that are expressed by NF-kB, a known master regulator of chronic inflammation. These molecules are critical for inflammation and cancer progression.
By inhibiting telomerase activity in primary cancer cells obtained from patient samples, the scientists found that levels of IL-6, an inflammatory molecule known to be a key driver of human cancers, was reduced in expression as well.
This is an important breakthrough that shows how targeting telomerase with drugs could potentially reduce inflammation, and hence get rid of cancer cells.
Dr Tergaonkar said, "These findings provide a unifying explanation for a decade worth of observations from leading laboratories in the field which show that chronic inflammation and telomerase hyperactivity co-exist in over 90 percent of human cancers. What we show that these two activities are actually interdependent. They also may lead to potentially novel drugs that will target a range of human ailments with inflammation as an underlying cause, which range from arthritis to cancer."
Prof Hong Wan Jin, Executive Director of IMCB, said, "The discovery speaks for the exceptional power of identifying novel mechanisms that have translational potential, through close collaborations among scientists in different A*STAR institutes, as well as to bring together both basic and clinical research scientists in Singapore. I am confident that we can expect more discoveries like this from Dr Tergaonkar's team."
Could This Be a "Silver Bullet" for Preventing and Treating Colon Cancer?News
A team of scientists targeted the gene CtBP with a drug known as HIPP (2-hydroxy-imino phenylpyruvic acid) and were able to reduce the development of pre-cancerous polyps by half.READ MORE
FDA Grants Full Approval to Blinatumomab for Acute Lymphoblastic LeukemiaNews
TheFDA has changed its accelerated approval of blinatumomab (Blincyto®) for some patients with acute lymphoblastic leukemia to a full approval and expanded the approved indications for its use.READ MORE
Understanding the Cellular Systems that Hold Back the Spread of CancerNews
Scientists have uncovered how cells are kept in the right place as the body develops, which may shed light on what causes invasive cancer cells to migrate.READ MORE
Comments | 0 ADD COMMENT
8th International Symposium on Recent Advances in Food Analysis (RAFA 2017)
Nov 07 - Nov 10, 2017
6th Edition of International Conference on Pharmacognosy and Medicinal Plants
Apr 16 - Apr 17, 2018
11th International Conference on Cancer Stem Cells
Jun 11 - Jun 13, 2018